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Accepted 23 August 1994The physiological actions of lobster peptide F1
(TNRNFLRFamide) have been examined on three different
lobster nerve–muscle preparations (exoskeletal, cardiac
and visceral). The peptide, which is found at high
concentrations in a lobster neurosecretory gland, causes a
long-lasting enhancement of contractility in each target
tissue. On exoskeletal nerve–muscle preparations, peptide
F1 has the following actions: (1) it potentiates transmitter
release from nerve terminals innervating exoskeletal
muscle, leading to an increase in both spontaneous and
nerve-evoked release of transmitter; (2) it acts directly on
the muscle, in the absence of nerve activity, to induce tonic
contractions; and (3) it shows a potent desensitization that
does not reverse with prolonged washing of the tissue. On
each of the types of muscle examined, peptide F1 is active
at nanomolar concentrations and is 3–4 orders of
magnitude more potent than FMRFamide. These findings
suggest that peptide F1 is a neurohormone with widespread
myogenic actions throughout lobster peripheral tissues.
The molecular mechanism(s) by which the peptide acts are
not yet known, but do not appear to involve cyclic AMP or
cyclic GMP.
Key words: TNRNFLRFamide, neuromodulation, crustacean
neuromuscular junction, crustacean heart, lobster, Homarus
americanus.
SummaryMore than 100 members of the invertebrate family of
FMRFamide-related peptides (FaRPs) have been identified,
all of which share the carboxy-terminal sequence –RFamide.
The first member of this family sequenced, the tetrapeptide
FMRFamide, was isolated from the molluscan central nervous
system (CNS) by Price and Greenberg (1977). Since that time,
short and long forms of these peptides have been isolated from
the nervous systems of many invertebrate species, including
echinoderms, annelids, nematodes, crustaceans and insects. In
addition, genes encoding precursors of these peptides have
been isolated and sequenced from several invertebrate species
(for a review, see Greenberg and Price, 1992). Vertebrate
members of this peptide family have also been isolated from
chick and bovine brain (Yang and Majane, 1990) and they
share sequence homology with the vertebrate family of opioid
peptides, raising the possibility that vertebrate FaRPs might
be active at opioid receptors. Indeed, when tested in specific
vertebrate model systems, FaRPs can act either as agonists or
as competitive antagonists at opiate receptors in different
tissues (Raffa, 1991; Raffa and Jacoby, 1990). A genetic
analysis of the FaRP precursor gene in Aplysia has led to the
suggestion that the invertebrate and vertebrate FaRPs and the
Introductionopioid peptides may have resulted from the divergent
evolution of common ancestral genes (Taussig and Scheller,
1986).
Physiologically, FaRPs mediate a wide and diverse set of
actions on multiple target tissues in many different
invertebrates. For example, members of the FaRP family
modulate neural activity in rhythmically active circuits such as
the stomatogastric ganglion of crustaceans (Hooper and
Marder, 1984; Marder et al. 1987; Weimann et al. 1993) and
alter the excitability of central neurons in molluscs (Ruben et
al. 1984; Thompson and Ruben, 1988; Brezina et al. 1987a,b;
Ichinose and McAdoo, 1988) and leeches (Simon et al. 1992).
FaRPs potentiate neurally evoked contractions of skeletal
muscle in locusts (Evans and Myers, 1986; Walther et al. 1984;
Cuthbert and Evans, 1989), moths (Kingan et al. 1990) and
crayfish (Mercier et al. 1990; Skerrett et al. 1995). They also
regulate nerve–muscle interactions in the shrimp
stomatogastric system, where the muscles are shifted from
quiescence through an oscillatory state of rhythmic
contractions, to a sensitized state in which the contractile
effects of neural inputs are amplified (Meyrand and Marder,
1991). In addition, FaRPs also have direct excitatory and
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molluscs (Painter and Greenberg, 1982), chelicerates (Groome,
1993), crustaceans (Krajniak, 1991; Mercier and Russenes,
1992; Skerrett et al. 1995), insects (Cuthbert and Evans, 1989)
and a leech (Norris and Calabrese, 1987, 1990; Thompson and
Calabrese, 1992).
In the decapod crustacean Homarus americanus, two
members of the FaRP family have been isolated and
characterized. TNRNFLRFamide (peptide F1) and
SDRNFLRFamide (peptide F2) were purified from the
neurosecretory pericardial organs, a site of high concentration
of these peptides in the lobster (Trimmer et al. 1987).
Immunocytochemical studies suggest that F1 and F2, or other
members of this family, are widely distributed in the lobster
nervous system, being found in peripheral neurosecretory
areas, within CNS neuropil regions and in a specific subset of
neuronal cell bodies in the CNS (Kobierski et al. 1987).
Peptide F1 is released from pericardial organs by
depolarization in the presence of calcium, is detected in the
hemolymph and is bioactive on various muscle tissues at low
concentrations, suggesting a possible neurohormonal role for
this peptide (Trimmer et al. 1987; Kobierski et al. 1987; Goy
et al. 1987a,b).
Peptides identical in sequence to F1 have been isolated only
from Homarus americanus and the crab Cancer borealis
(Weimann et al. 1993), although a similar peptide is reported
to be present in the spiny lobster Panuliris interruptus
(Marder et al. 1987). A closely related peptide
(NRNFLRFamide) has been purified from crayfish
pericardial organs (Mercier et al. 1993). Interestingly,
structure/activity studies in several species have shown that
peptide F1 is the most potent of all FaRPs tested in
stimulating contractility in various neuromuscular
preparations, including the heart in blue crabs (Krajniak,
1991), the heart and extensor tibialis skeletal muscle of
locusts (Cuthbert and Evans, 1989), the stomatogastric
muscles of shrimps (Meyrand and Marder, 1991) and the
phasic skeletal muscles of crayfish (Mercier et al. 1990). In
fact, in certain of the species in which endogenous
FMRFamide-related peptides have been isolated, F1 is more
potent than the purified native peptides.
In this paper, the physiological effects of peptide F1 are
tested on three different nerve–muscle preparations from the
lobster Homarus americanus. In heart, oesophageal muscle
and exoskeletal muscle preparations, peptide F1 induces or
augments contractility. In exoskeletal muscle preparations,
pre- and post-junctional effects are seen and the peptide is
about three orders of magnitude more potent than
FMRFamide. In all the preparations, peptide F1 is active at
nanomolar concentrations, consistent with its postulated
neurohormonal role. A preliminary report has been published
describing the results presented here (Goy et al. 1987b). In
an accompanying paper, Skerrett et al. (1995) describe
similar effects of the related crayfish peptides (NF1,
NRNFLRFamide; and DF2, DRNFLRFamide) on crayfish
target tissues.Materials and methods
Animals and tissues
Lobsters (Homarus americanus Milne Edwards) of both
sexes weighing approximately 0.5 kg were purchased locally
and held in artificial sea water (Instant Ocean, Aquarium
Systems, Mentor, OH) at 12–14 ˚C. All tissues were dissected
in ice-cold lobster saline (462 mmol l21 NaCl, 16 mmol l21
KCl, 26 mmol l21 CaCl2, 8 mmol l21 MgCl2, 11 mmol l21
glucose, 10 mmol l21 Tris–maleate or Hepes, pH 7.4).
Exoskeletal muscle
The dactyl opener muscle and its associated excitatory and
inhibitory nerves in the propopodite segment of the walking
leg were exposed by removing overlying exoskeleton, muscle
and sensory nerves, as described by Glusman and Kravitz
(1982).
Heart
The heart was isolated by cutting dorsally through the
thoracic carapace, removing a small section of exoskeleton
with the heart attached and dissecting away surrounding
tissues. The sternal artery was cannulated for perfusion, as
described previously (Battelle and Kravitz, 1978).
Oesophagus
The oesophagus was isolated as a ring of muscle from the
anterior part of the gut and cut from its posterior end to produce
a flat sheet. The muscle was isolated together with the pair of
circumoesophageal ganglia and the single suboesophageal
ganglion attached.
Tension measurements and intracellular recording
Isolated preparations were superfused continuously with
lobster saline at 10–13 ˚C (2–3 ml min21), to which hormones
were added at the concentrations indicated. Based on the
latency to muscle contraction in response to bath application
of high-K+ saline, the exchange time of the bath by the
perfusion system can be estimated as 1–2 min. Muscle tension
was measured almost isometrically by fastening the apodeme
of the muscle to a Grass FT03 force transducer with surgical
thread. Quantitative tension measurements were made by
calibrating the force transducer and measuring the force
exerted at the peak of the contractile response in units of grams.
For intracellular recordings, muscle fibers were penetrated with
3–5 MV glass microelectrodes filled with 2–4 mol l21
potassium acetate. Muscle fiber resting potentials ranged from
255 mV to 280 mV; recordings from fibers with resting
potentials outside this range were discarded. Nerves were
stimulated extracellularly, using suction electrodes. Membrane
potential changes were recorded differentially between the
microelectrode and the bath, grounded through a silver/silver
chloride electrode. The force transducer and electrode outputs
were amplified and recorded on tape, using an audio tape
recorder (Hewlett-Packard 3968A Instrumentation Recorder)
or a VCR (VR-100A Digital Recorder, Instrutech Corp).
Tension recordings, excitatory (EJP) and inhibitory (IJP)










Fig. 1. Peptide F1 potentiates contractions and muscle tonus in an
exoskeletal muscle preparation. (A) Muscle tension recorded from the
dactyl opener muscle of the lobster walking leg. Upward vertical
deflections in the record are twitch contractions evoked by firing brief
trains of action potentials (30 Hz, 0.3 s) in the excitatory nerve at 10 s
intervals. Peptide F1 was applied as indicated by the horizontal bar.
The slow upward shift in baseline tension represents the peptide-
induced increase in muscle tone and can be observed both in the
presence and in the absence of nerve-evoked twitch contractions (see
Fig. 3). (B) A different dactyl opener preparation in which muscle
tension was recorded during stimulation of the excitatory nerve
(35 Hz, 0.3 s) at 10 s intervals. The peptide increases twitch
contraction strength in this preparation without increasing muscle
tone.junctional potentials and miniature EJPs (MEJPs) were
digitized and analyzed using a microcomputer with VR111
(Instrutech Corp.) and pClamp software (Axon Instruments).
Cyclic nucleotide measurements
For measurement of heart cyclic nucleotide levels, intact
cardiac ganglia were obtained from the inner chambers of the
hearts of several animals and the remaining heart muscle was
cut into several pieces of approximately equal size. Exoskeletal
muscles were obtained from walking legs of several animals
as described above, except that the excitatory and inhibitory
nerves were dissected from the surface of the muscles and
discarded. When possible, dissected tissues were divided so
that control and experimental groups contained samples from
all animals. All experiments included a 2 h preincubation in
lobster saline containing 0.5 mmol l21 isobutyl methylxanthine
(IBMX), followed by a 15 min exposure to test hormones in
the same medium. At the end of the incubation period, each
piece of tissue was frozen in methanol at 280 ˚C and
immediately homogenized in ice-cold 6 % trichloroacetic acid.
Samples were processed and analyzed for cyclic AMP or cyclic
GMP content by radioimmunoassay (procedures and materials
obtained from New England Nuclear and Biomedical
Technologies, Inc.; see Goy et al. 1984, 1987a).
Trypsin digestion of peptide F1
Peptide F1 (531024 mol l21) was incubated with trypsin
(50 mg ml21) for 15 min at 21 ˚C. The sample then was heated
to 60 ˚C for 1 min to inactivate the trypsin and diluted 1:2000
in lobster saline for application to an exoskeletal muscle
preparation (final concentration of peptide: 2.531027 mol l21).
As a control, trypsin (50 mg ml21) was heat-inactivated,
diluted as above, and applied independently to the preparation.
See legend to Fig. 2 for details.
Chemicals
Isobutylmethylxanthine (IBMX) was obtained from Aldrich,
serotonin creatinine sulfate from Sigma and peptide F1
(TNRNFLRFamide) and FMRFamide from Peninsula
Laboratories. Some experiments were performed using peptide
F1 synthesized by Neosystems Laboratories (France). The
results of experiments using peptide F1 from either source were
identical. All other chemicals were reagent grade, obtained
from commercial suppliers.
Results
Peptide F1 (TNRNFLRFamide) is an endogenous
octapeptide found in, and released from, lobster pericardial
organs. Because of the known neurohemal role served by
pericardial organs, we examined the physiological effects of
the peptide on three potential peripheral targets of this
substance: exoskeletal muscle, heart and oesophagus.
Exoskeletal muscle
In the dactyl opener muscle, single EJPs and brief low-frequency (<5 Hz) trains of EJPs are insufficient to produce
changes in muscle tonus, whereas higher-frequency trains of
facilitating EJPs evoke twitch contractions. When applied to
the dactyl opener muscle, peptide F1 elicits both an increase in
muscle tone and an increase in the strength of nerve-evoked
twitch contractions (Fig. 1A). These responses develop over a
period of 5–10min and can persist after washout of the peptide
for up to 30 min. In some preparations, particularly at low
doses, the increase in twitch contraction strength occurs
without a change in muscle tone (Fig. 1B), indicating that the
potentiation of twitch contractions is not secondary to the
change in muscle tone.
To investigate the effects of the peptide on synaptic
transmission and muscle membrane properties, recordings
were made from individual fibers with intracellular
microelectrodes. In the experiment shown in Fig. 2, stimuli
were applied to both the excitatory and inhibitory nerves at a
frequency too low to induce twitch contractions (single pulses
at 0.2 Hz) and synaptic potentials were recorded. Peptide F1
enhances the size of both EJPs and IJPs (Fig. 2, top trace) with
a time course that parallels the increase in muscle tone (not
shown). These effects reverse as the peptide is washed from
the preparation.
To verify that the physiological effects observed were due
to the intact octapeptide, the peptide was treated with trypsin
before applying it to a neuromuscular preparation (Fig. 2).
Trypsin treatment should cleave peptide F1 at its arginine
residues and render it biologically inactive. Consistent with
this expectation, the effects of the peptide on synaptic potential
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Fig. 2. Synaptic transmission is enhanced by
peptide F1. An intracellular recording from a
muscle fiber is displayed at a very slow time
scale in which individual synaptic responses
cannot be resolved. (Boxed inset shows
averaged representative responses of 50
traces taken during the periods denoted by
the shaded bars at higher sweep speed.)
Upward deflections from the baseline are
EJPs, downward deflections are IJPs. The
break in the record indicates a 1 h wash-out
period during which no data were collected.
Muscle resting potential was 268 mV. Bars
below the traces indicate the presence of the
following agents in the saline superfusing the
preparation (from left to right): peptide F1
(531028 mol l21), heat-inactivated trypsin,
peptide F1 (2.531027 mol l21) preincubated
in trypsin and subsequently heat-treated to
inactivate the trypsin (see Materials and
methods), peptide F1 (2.531027 mol l21).
Note that in this experiment the response to
a second application of peptide F1 is roughly
50 % of the initial response, although the
















Fig. 3. Peptide F1 increases muscle tone. Tension was recorded from
the dactyl opener muscle in the absence of nerve stimulation.
Horizontal bars indicate bath applications of 531027 mol l21 peptide
F1. Note that the second peptide application is ineffective at inducing
muscle contraction.amplitude were eliminated by pretreatment with trypsin
(Fig. 2). This confirms that the intact N-terminally extended
sequence is important for biological activity and rules out the
possibility that the effects we see are due to a non-peptide
contaminant in the synthetic peptide preparation.
The intracellular recording of Fig. 2 also illustrates an
unusual feature of the actions of this peptide: the direct effects
of the peptide on synaptic transmission are fully reversible, but
a single application of the peptide strongly desensitizes the
preparation to subsequent applications. In three experiments in
which EJP size was monitored, the facilitation produced by a
second exposure to 531028 mol l21 peptide F1 was
approximately 54.0±23.3 % of that produced by the initial
exposure; a third response was 22.0% of the initial size (N=1).
This desensitization was also apparent in experiments in
which muscle tone was measured. An extreme example of the
desensitization of the muscle contractile response to peptide F1
is shown in the tension recording in Fig. 3, in which a second
application of peptide was completely ineffective at
stimulating an increase in muscle tone. In four experiments in
which muscle tension was measured, a second application of
531028 mol l21 peptide stimulated a contractile response
averaging 42.9±10.3 % of the initial response; a third response
was 26.0±5.5 % of the initial size (N=2). Washing preparations
for as long as 4 h between exposures was insufficient to permit
recovery. Owing to the long-lasting nature of the
desensitization and the intrinsic variability between
preparations, it has not been possible to establish a quantitative
correlation between the concentration or duration of the initial
exposure to peptide and the extent of desensitization. A similar
desensitization of the synaptic potential and muscle tension
response has not been observed for serotonin, octopamine andproctolin, the other neurohormones that modulate this
neuromuscular system (Kravitz, 1986).
No consistent effects on membrane potential were seen in
muscle preparations treated with peptide F1 (20 experiments).
While occasional slow changes in membrane potential of small
amplitude were observed (less than 2 mV), these were in
hyperpolarizing or depolarizing directions with equal
frequency. It is likely, therefore, that they result from
movement of the preparation, or from electrode drift over the
course of the experiment, and are not a consequence of
treatment with the peptide. In one preparation in which resting
potentials were measured before and after peptide treatment
(2.531028 mol l21 F1 for 13 min), the resting potentials of
muscle fibers recorded under control conditions
(271.2±6.7 mV; N=11) did not differ from those recorded in
the presence of the peptide (272.7±5.7 mV; N=7).
To test whether the peptide alters muscle membrane
resistance, periodic hyperpolarizing current pulse injections

























Fig. 4. Peptide F1 increases EJP size
without increasing muscle input resistance.
The excitatory motoneuron innervating the
muscle was stimulated at 0.1 Hz. Following
each stimulus (with a 300 ms delay), a
hyperpolarizing current pulse was
delivered to the muscle fiber through the
recording electrode. The histogram shows
the sizes of EJPs (open bars) and voltage
responses (filled bars) to current injection.
Each bar is the mean value (+ S.E.M.) for 20
sequential responses; the standard errors for
the current injection measurements are too
small to be observed on this scale. The inset
shows average traces of EJPs and voltage
responses to current injections. The open
circles were recorded in control saline; the
filled circles were recorded after 10 min of
exposure to the peptide (N=5 for both). The
horizontal box indicates the period during
which peptide F1 (531028 mol l21) was





10 mVwere delivered through the intracellular microelectrode while
membrane potential and muscle tension were monitored. The
analysis of an experiment in which nerve-evoked EJPs and
muscle input resistance were measured every 5 s as the
preparation was superfused with peptide is shown in Fig. 4.
Muscle input resistance (filled bars, Fig. 4) did not change
during the period in which peptide F1 induced increases in EJP
size (open bars, Fig. 4) and muscle tone (not shown). The inset
illustrates averaged EJP and current pulses recorded in control
saline and after 10 min of exposure to the peptide. Peptide F1
increased the amplitude of the EJP by 41 %, while the voltage
response elicited by current injection was not changed.
Identical results were obtained in three other experiments in
which muscle input resistance was measured.
To examine whether peptide F1 acts at a presynaptic site to
enhance synaptic transmission, parallel measurements were
made of peptide effects on nerve-evoked transmitter release (in
response to brief trains of stimuli) and on spontaneous
transmitter release (MEJPs, measured in the periods between
stimuli). As shown in previous experiments, superfusion of
peptide F1 over the preparation increases EJP amplitudeFig. 5. Effects of peptide F1 on transmitter release from the excitatory
motoneuron. (A) EJP trains recorded intracellularly under control
conditions and at the peak of the peptide-induced increase in twitch
contractions (after 8min of exposure to 231028 mol l21 peptide). EJP
sizes are increased in the presence of the peptide. Muscle resting
potential was 276 mV. (B) A histogram of miniature EJPs (MEJPs)
recorded in the same preparation under control conditions (open bars)
and at the time of maximal peptide-induced increase in twitch
contraction strength (filled bars). Note that MEJP frequency increases
approximately 50 % with no change in size distribution. MEJPs were
recorded for 120 s under each experimental condition.(Fig. 5A). Fig. 5B shows the amplitudes and numbers of
MEJPs recorded in the same neuromuscular preparation under
control conditions (normal saline: open bars) and after 8 min
of exposure to peptide F1 (filled bars). In the presence of
peptide F1, the number of MEJPs recorded increases by 50 %
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Table 1. Effects of peptide F1 on mean quantal variables
EJP size Quantal size MEJP frequency
(mV) (mV) Quantal content (s−1)
Control First EJP 3.01±1.58 1.80±0.20 1.67±0.88 3.8
(N=21) Last EJP 49.30±1.53 – 27.38±0.85 –
Peptide F1 First EJP 4.81±1.37* 1.80±0.20 2.67±0.76* 5.8
(N=21) Last EJP 59.27±3.22* – 32.93±1.79* –
The excitatory motoneuron was simulated at a rate of 35 Hz for 0.3 s at a train rate of 0.1 Hz; EJP size was measured for the first and the last
EJP of each train.
The control and experimental values given above were determined for 21 trains under control conditions and after 12 min of exposure of the
peptide (2×10−8 mol l−1).
Quantal size was determined by measuring MEJP size during the interval between trains for 120 cumulative seconds under each condition.
MEJP frequency was calculated by dividing the number of observed MEJPs by the total recording time.
Quantal content (m) was calculated by dividing mean EJP amplitude by quantal size.
Data in this table were obtained from the experiment shown in Fig. 5.
*Experimental values are significantly different from control values in a t-test (P<0.001).
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Fig. 6. Peptide F1 increases the amplitude of EJPs at a lower
concentration than does FMRFamide. Each circle is the calculated
ratio of the average EJP amplitude in the presence of peptide to the
average control EJP amplitude (i.e. EJP size in the presence of
peptide/control EJP size). Averages were calculated from 20
sequential EJP records, the standard error for this measure was always
less than 15% of the mean (see Fig. 4, for example). The filled circles
are ratios calculated for preparations exposed to peptide F1, while the
open circles are ratios calculated for preparations exposed to
FMRFamide. Each ratio was calculated from the response of a single
preparation to the initial exposure to the peptide.of the mean quantal content of the evoked release based on the
MEJP size (Table 1) indicates that treatment with the peptide
increases the quantal content of release. These results suggest
that the peptide potentiates synaptic transmission by enhancing
the probability of release, rather than by increasing the
postsynaptic sensitivity of the muscle to the neurotransmitter
(see also Skerrett et al. 1995).
As shown in Fig. 2, peptide F1 increases the sizes of the IJPs
and of the EJPs. An analysis of the effects of peptide F1 on
IJPs is complicated by the fact that the muscle fiber resting
potential is close to the chloride equilibrium potential. In
several experiments (not shown), two electrodes were inserted
into a single muscle fiber, one to pass depolarizing and
hyperpolarizing current and the other to record IJP amplitude
as a function of membrane potential. Peptide treatment
increases the size of IJPs on both sides of the reversal potential,
with no change in the reversal potential itself. This result, and
the observations that peptide F1 causes no consistent changes
in muscle fiber resting potential or input resistance, suggests
that the peptide potentiates the release of transmitter from
inhibitory as well as from excitatory nerve terminals.
To examine whether the peptide is physiologically active in
a concentration range consistent with that expected for a blood-
borne neurohemal agent, the effects of peptide F1 on EJP
amplitude were measured over a range of concentrations. To
eliminate the influence of desensitization of responses with
repeated peptide applications (see above), data were collected
only during the initial peptide application in each preparation.
The effects of the peptides were measured by averaging 20
sequential records (to minimize the influence of quantal
fluctuations) and determining the ratio of the response in the
presence of peptide to the control response. Fig. 6 shows that
both peptide F1 and FMRFamide increase EJP amplitude, with
peptide F1 eliciting increases in EJP size at concentrations 100-
fold lower than does FMRFamide. The threshold for the
response to peptide F1 on this preparation is in the vicinity of
1029 mol l21. This threshold concentration is similar to thatdetermined for other neurohormonal agents on this preparation
(Battelle and Kravitz, 1978; Schwarz et al. 1980).
Comparisons between the actions of peptide F1 and
serotonin
In a general way, the actions of peptide F1 resemble those
of serotonin on this tissue (see Goy and Kravitz, 1989). Both
substances enhance the contractility of exoskeletal muscles and




















































































Fig. 7. Response of exoskeletal muscle to sequential repeated
applications of peptide F1 and serotonin. The bars indicate the
maximal contractions generated by the muscle in the presence of each
agent tested. The open bars indicate the responses to serotonin (5-HT),
the black bar indicates the response to peptide F1, the shaded bar
indicates the response to saline containing an elevated K+
concentration. The duration of each application of peptide or amine
was at least 10 min, and each application was followed by a 1 h period
of washing in normal saline. ND indicates that no muscle response
was detected.increase transmitter release from excitatory and inhibitory
nerve terminals. This raises the question of whether the two
substances share a common signal transduction pathway. To
address this, we have compared in detail several of the features
of the physiological responses to peptide F1 and serotonin.
An unusual feature of the peptide F1 response is its profound
desensitization during repeated applications (see Figs 2 and 3).
Although this type of desensitization has never been described
for serotonin, it seemed important to test the actions of the twoFig. 8. Effects of peptide F1 and
serotonin on nerve-evoked muscle
contractions and relaxations.
Muscle tension was recorded in
response to alternating trains of
stimuli delivered to the excitatory
and inhibitory motoneurons;
upward deflections show the
twitch contractions, downward
deflections show the muscle
relaxations. Sample tension
records are shown in control saline
(left side of figure) and after
12 min of exposure to peptide F1 or
serotonin (right side of figure); all
traces are from a single
preparation. Both hormones
potentiate the size of twitch
contractions and stimulate a slight
increase in muscle tonus. (The
dotted line indicates resting tension.) Serotonin also potentiates the stren
with the schematic bars at the bottom of the figure that show the timing
to the inhibitory (I) motoneurons innervating the muscle. Stimulation r





Serotoninsubstances in parallel experiments on single preparations. In
Fig. 7, the tension responses of a preparation to alternating
applications of amine and peptide are shown. Only the initial
application of peptide F1 elicited muscle contraction in this
preparation: no response was seen to later applications, even
at higher concentrations. In contrast, contractions can
repeatedly be triggered by the application of serotonin and are
observable even after the peptide is no longer effective. A
similar disparity in the contractile effects of the two agents has
been observed in four experiments of this type. It is apparent,
therefore, that the peptide and amine responses do not cross-
desensitize.
A further comparison of the peptide and amine effects is
shown in Fig. 8. Here tension is monitored while alternating
trains of stimuli are applied to the excitatory and inhibitory
nerves innervating the muscle. The twitch contractions elicited
by stimulation of the excitatory nerve are equally potentiated
by peptide F1 and serotonin, but the muscle relaxations elicited
by stimulating the inhibitory nerve are much larger in the
presence of serotonin. Thus, while both hormones induce an
increase in resting muscle tone and twitch tension strength, the
response of the muscle to inhibitory motoneuron activity is
differentially modulated by the amine and the peptide.gth of nerve-evoked muscle relaxations. The tension traces are aligned
 of brief trains of stimuli alternately delivered to the excitatory (E) and
ate for excitatory motoneuron, 35 Hz, 0.3 s; for inhibitory motoneuron,
E E E E
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Fig. 9. Effects of peptide F1 and serotonin (5-HT) on muscle tone and
nerve-evoked relaxations. All traces show the muscle tension
recorded while the inhibitory motoneuron innervating the muscle is
stimulated (50 Hz for 0.5 s at a train rate of 0.05 Hz); the downward
deflections of the tension trace show stimulus-induced relaxations.
(A) 331027 mol l21 peptide F1 increases muscle tone and induces a
small increase in nerve-evoked relaxations. (B) The response of the
same preparation to bath applications of serotonin. When muscle tone
is increased to approximately the level shown in the peptide F1 tension
trace, the nerve-evoked relaxations are strongly potentiated. (C) The
response of a different preparation to application of a depolarizing K+
concentration (22 mmol l21 KCl) and to 331027 mol l21 peptide F1.
Both agents increase muscle tone without strongly affecting nerve-
evoked muscle relaxations.
 
To emphasize these differences, the experiment shown in
Fig. 8 was repeated in preparations in which only inhibitory
nerves were stimulated and the measurements of muscle tone
were not interrupted by twitch contractions. Under these
conditions, when peptide F1 increased muscle tone it also
slightly enhanced nerve-evoked relaxations (Fig. 9A). In the
same preparation, serotonin strongly potentiated nerve-evoked
relaxations (Fig. 9B) at a dose eliciting a tonic contraction
comparable to that induced by peptide F1. Next, to test the
effect of contraction alone on the inhibitory nerve-evoked
relaxations, a different preparation was bathed in saline
containing an elevated level of K+ in order to generate a
contraction of a similar size to the ones induced by the testFig. 10. Physiological
actions of peptide F1 on the
heart. (A) Tension records
from a spontaneously
beating heart. The chart
speed is slow so that the
individual heartbeats have
fused; the envelope of each
trace gives the amplitude of
the heartbeat as a function
of time. Peptide F1 was
applied at the indicated
concentration for the
intervals specified by 
the horizontal bars. 
(B) Dose–response curve
for peptide F1 (d) and
FMRFamide (s) on heartbeat strength. The data points are the amplit
pre-stimulus amplitude. The data are pooled from experiments on thr
peptide F1 on the same preparation. The peptides also increase the he





substances (Fig. 9C). Raising K+ levels in the bathing solution
should lead to muscle fiber depolarizations, which should in
turn increase the size of the IJPs. The relaxations resulting from
stimulating the inhibitory nerve under these conditions are
larger than in the control conditions, but similar in size to those
elicited during a peptide F1-induced contracture; both are much
smaller than the relaxations seen during serotonin-induced
contractures.
Thus, despite superficial similarities in the actions of peptide
F1 and serotonin on these preparations, the important
differences in their physiological actions shown above suggest
that the two neurohormonal substances do not share a common
mechanism of action.
Peptide F1 effects on other contractile tissues
Peptide F1 increases both the rate (not shown) and strength
of the heartbeat (Fig. 10A), with a threshold that is 3–4 orders
of magnitude below that of FMRFamide (Fig. 10B). The
effects can be large (two- to threefold increases in the
amplitude of the heartbeat), and they persist for several
minutes after the peptide has been washed from the bath.ude of the heartbeat at the peak of the response as a percentage of the
ee different preparations. FMRFamide was always less effective than
























Concentration of peptide (mol l–1)
10–10 10–9 10–8 10–7 10–6 10–5
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Table 2. Cyclic AMP and cyclic GMP levels in lobster tissues after hormone treatment
Cyclic AMP level Cyclic GMP level
Tissue Treatment (pmol mg−1 protein) (pmol mg−1 protein)
Dactyl opener None 29.3±6.3 (N=12) 0.40±0.02 (N=3)
muscle 10−7 mol l−1 peptide F1 30.3±8.5 (N=4) 0.31±0.06 (N=3)
0.39±0.04 (N=3)*
10−4 mol l−1 FMRFamide 25.5±11.3 (N=3) −
10−6 mol l−1 serotonin 80.3±6.7 (N=6) –
Peptide G1† – 4.73±0.44 (N=3)*
Cardiac ganglion None 39.4±2.0 (N=4) –
10−7 mol l−1 peptide F1 31.2±2.8 (N=3)
Heart muscle None 84.2±19 (N=9) –
10−7 mol l−1 peptide F1 83.0±13 (N=11)
Except where indicated, each tissue was treated for 15 min with the indicated concentration of peptide or amine in the presence of IBMX, as
described in Materials and methods.
Values are the mean ± S.E.M. for the number of determinations given in parentheses.
*Measurement made after treatment with peptide for 90 min.
†Saturating dose, as determined by bioassay (Pavloff and Goy, 1990).Surprisingly, the desensitization described above in this study
of the effects of peptide F1 on exoskeletal muscle is not
observed in the responses of the heart. During prolonged
exposures to high concentrations of peptide, however, the
amplitude of the enhancement often declines (see lower traces
Fig. 10A). This may represent a slow adaptation to the peptide
or it may represent fatigue, since the amplitude of the heartbeat
is sometimes irreversibly depressed after the washout of high
doses of the peptide. The oesophagus, a visceral muscle, was
also examined as a potential target for peptide F1. In three
experiments, the peptide increased basal tension and either
initiated or augmented rhythmic contractile activity (data not
shown).
Cyclic nucleotides and peptide F1
In many invertebrate and vertebrate preparations, hormones
that elevate cyclic AMP levels enhance neurosecretion and/or
alter muscle contractility (see Goy and Kravitz, 1989, for a
review). Moreover, in molluscan heart muscle, FMRFamide
elevates cyclic AMP levels in parallel with its physiological
actions (Higgins, 1977; Higgins et al. 1978; Painter, 1982b).
We therefore tested peptide F1 and FMRFamide for their
effects on cyclic AMP levels in various lobster tissues
(Table 2). Both peptides failed to increase cyclic AMP levels,
while serotonin generated a readily detectable increase.
Another second-messenger system that may play a role in
muscle contractility in vertebrates (George et al. 1970; Lee et
al. 1972; Rapoport and Murad, 1983) and invertebrates (Beam
et al. 1977; Painter, 1982a; Matsuura, 1984) is cyclic GMP.
We therefore examined whether peptide F1 might stimulate
cyclic GMP levels in the dactyl opener muscle, the tissue
which is the main focus of these studies. When tested at
1027 mol l21, a high concentration compared with the
physiological threshold, peptide F1 has no effect on cyclic
GMP levels measured in isolated neuromuscular preparations
(Table 2). In contrast, parallel incubations with peptide G1(Pavloff and Goy, 1989) produced substantial increases in
cyclic GMP levels. These results suggest that neither cyclic
AMP nor cyclic GMP is a good candidate for mediating the
effects of peptide F1. We cannot rule out the possibility,
however, that the peptide raises cyclic nucleotide levels in
some restricted tissue compartments where the nucleotide
content is small relative to the total background levels of
nucleotides.
Discussion
In this study, the lobster peptide F1 has been found to
modulate several aspects of nerve–muscle function. In a
skeletal muscle preparation, peptide F1 increases the strength
of neurally evoked twitch contractions and acts directly on
skeletal muscle fibers to induce sustained increases in tone in
the absence of evoked nerve activity. The tonic muscle
contractions induced by peptide F1 are independent of the
activity of the excitatory motoneuron, since they are observed
under conditions where stimulation frequency of the excitatory
motoneuron is sufficiently high to evoke twitch conditions
(Fig. 1A) and when there is no stimulation of the excitatory
motoneuron (Figs 3, 7 and 9). In addition to potentiating
muscle contractility, peptide F1 presynaptically enhances
transmitter release from the motoneurons innervating the
muscle, resulting in an increase in the sizes of EJPs and IJPs
recorded postsynaptically. Peptide F1 also augments
contractility in lobster cardiac and visceral muscle
preparations, although the mechanism of these actions has not
been studied extensively. Taken together, these results suggest
that this peptide may play a general role in lobsters as a
systemic neurohormone.
A similar potentiation of neurally evoked contractions by
members of the FaRP family has been seen in neuromuscular
preparations from locusts, crayfish and moths (Cuthbert and
Evans, 1989; Schiebe and Walther, 1989; Kingan et al. 1990;
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of transmitter release has been shown previously for the lobster
peptides F1 and F2 and their crayfish analogs N1 and D2 in a
crayfish phasic neuromuscular system (Mercier et al. 1990;
Skerrett et al. 1995). In each case, FaRPs increase the
probability of transmitter release, with no effect on the
postsynaptic responsiveness of the muscle to the released
transmitter compound. In contrast, in studies with snail
muscles and neurons, FMRFamide has been shown to reduce
the responsiveness of muscles to the excitatory transmitter
acetylcholine (Zoran et al. 1989) and to inhibit
neurotransmission between neurons via a presynaptic
mechanism (Haydon et al. 1991). Thus, members of the FaRP
family may potentiate or suppress synaptic effectiveness and
muscle contractility in different neuromuscular systems in
different organisms.
While the actions of peptide F1 on lobster synaptic
transmission and twitch contractions are similar to those
reported in other muscle systems, a direct stimulation by FaRPs
of tonic skeletal muscle contractions has not been reported
previously. The mechanism by which the peptide generates
contractures of this type is not known. One possibility is that
they are a consequence of the peptide-F1-mediated increase in
frequency of spontaneous transmitter release from the
excitatory motoneuron innervating the muscle (see Fig. 5).
However, no changes in muscle membrane potential or input
resistance are seen accompanying the contractures, both of
which would result from a neurotransmitter-mediated
mechanism. This suggests that the contractures result from
direct actions on the muscle fibers through mechanisms that are
independent of membrane voltage. These observations also rule
out a mechanism of the type observed in leech heart muscle,
where FaRPs directly induce an inward Na+ current. This
current depolarizes muscle fibers into a voltage range in which
excitation–contraction coupling is activated and modulation of
voltage-dependent K+ and Ca2+ conductances becomes
apparent (Thompson and Calabrese, 1992).
One way in which peptide F1 might regulate muscle tone is
suggested by a report that tetrapeptides of the FaRP family
inhibit a Na+/Ca2+ exchanger in vertebrate cardiac muscle
sarcolemmal vesicles (Khananshvili et al. 1993). In cardiac
muscle, the sarcolemmal Na+/Ca2+ exchanger plays an
important role in the electrogenic extrusion of intracellular
Ca2+, thereby influencing muscle tone and relaxation. If a
similar exchanger protein is present in the sarcolemma of
lobster skeletal muscle fibers and if it is inhibited by peptide
F1, the resulting increase in intracellular Ca2+ concentration
could activate a number of Ca2+-dependent processes that
might regulate muscle tone and contractility. For example,
increases in cytoplasmic Ca2+ concentration could (1)
stimulate enzymatic pathways or second-messenger cascades;
(2) regulate muscle contractile proteins; or (3) potentiate the
release of Ca2+ from internal stores. Further studies will be
required to explore these and other such possibilities.
The long latency to onset and persistent effects of the
peptide in increasing muscle tone suggest the involvement ofa second-messenger system, but the appropriate second
messenger has not yet been identified. The cyclic nucleotide
systems appear to be unlikely, as neither cyclic AMP nor cyclic
GMP levels are elevated by the peptide in any lobster tissues
tested. Peptide F1, therefore, is one of several neuromodulators
of the dactyl opener system (including the amines serotonin
and octopamine and the peptide proctolin) for which the
cellular mechanism of contractile activation is unknown
(Kravitz et al. 1985; Goy and Kravitz, 1989). The skeletal
muscle responses to peptide F1 differ from those produced by
the other lobster neurohormones, however, in that the muscle
and nerve terminal responses desensitize with repetitive bath
applications of the peptide. Little is known of the mechanism
of desensitization in either nerve or muscle. In muscles,
however, it apparently is not at the level of activation of the
contractile proteins, since muscles desensitized to peptide F1
continue to respond to neural stimulation and to bath
application of other hormones (see Fig. 7). Furthermore,
although the contractile effects of the peptide on exoskeletal
muscle desensitize strongly, those on the heart can be elicited
repeatedly with little decrease in potency. The desensitization
phenomenon is therefore tissue-specific. Similar observations
have been made in crayfish studies with analogs of peptide F1.
Here too, the peptide effects on neuromuscular transmission
decline with repetitive application but no desensitization is
observed in studies of heartbeat amplitude or rate (Skerrett et
al. 1995). These observations raise the possibility that multiple
receptor types or second-messenger systems may mediate the
actions of these substances. Such a possibility is consistent
with the findings that the pharmacological profiles of locust
heart and skeletal muscle show differences in response to
particular FaRP sequences (Cuthbert and Evans, 1989).
The pericardial organs, segmentally arranged pairs of
neurosecretory glands found within the pericardial sinus at the
openings of the branchiocardiac veins, are an important site of
FaRP accumulation in lobsters (Trimmer et al. 1987). When
applied to the lobster heart in nanomolar concentrations,
peptide F1 increases both the amplitude and the frequency of
the heartbeat. This raises the possibility that the release of
peptide F1 from pericardial organs is one important way of
regulating cardiac activity in vivo. Cardioexcitatory effects of
peptide F1 have also been observed on locust heart (Cuthbert
and Evans, 1989), crab heart (Krajniak, 1991) and crayfish
heart (Mercier et al. 1990). In each of these systems, peptide
F1 was more potent than any other FaRP tested and at least an
order of magnitude more potent than the tetrapeptide
FMRFamide. It is not known whether the peptide is acting on
neurons of the cardiac ganglion that provide pacemaker
activity to the heart or on heart muscle directly. An increase in
heartbeat amplitude could reflect actions on either tissue, but
an increased heart rate probably reflects a change in ganglionic
neuronal activity. Effects of FaRPs on the neuronal networks
that function as pattern generators or bursting pacemakers have
been described in the leech heart (Kuhlman et al. 1985),
Aplysia buccal and abdominal ganglia (Sossin et al. 1987;
Ruben et al. 1984) and the lobster and crab pyloric and gastric
107Actions of lobster peptide F1rhythm central pattern generators (Hooper and Marder, 1984;
Weimann et al. 1993).
In summary, peptide F1 acts at low concentrations to
potentiate synaptic transmission and to regulate the
contractility of skeletal, cardiac and visceral muscles in
lobsters. These observations, and the demonstration that
neurosecretory regions are rich sources of such peptides,
suggest that peptides of this family act as blood-borne
hormones capable of influencing multiple peripheral targets in
lobsters. These results are consistent with an emerging picture
of FaRPs as important regulators of nerve and muscle activity
in a wide variety of invertebrate species. In Homarus, peptide
F1 is only one of several neurohormones that influence muscle
contractility and nerve–muscle communication. Understanding
the behavioral contexts in which peptide F1 and related
peptides are released, and elucidating the cellular mechanisms
by which they act, remain significant challenges for the future.
The three authors contributed equally to this work and the
order of authorship is therefore arbitrary. We thank Dr John
Hackett for helpful discussions. This investigation was
supported by a Program Project Grant from the NIH
(NS25915).
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